VolitionRX Ltd(VNRX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 4 at 5:19 AM ET (Korea 11/4 19:19)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.84 | Insider Own | 4.77% | Shs Outstand | 27.9M | Perf Week | 4.32% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 62.15% | Insider Trans | - | Shs Float | 26.6M | Perf Month | -16.81% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.38 | Inst Own | 7.25% | Short Float | 4.31% | Perf Quarter | -75.72% |
| Income | -0.03B | P/S | 2.19 | EPS this Y | 55.97% | Inst Trans | 1.02% | Short Ratio | 0.13 | Perf Half Y | -91.72% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 57.2% | ROA | -306.96% | Short Interest | 1.15M | Perf YTD | -96.22% |
| Book/sh | -2.67 | P/C | 1.93 | EPS past 3/5Y | 26.33% 13.42% | ROE | - | 52W High | -97.97% ($9.50) | Perf Year | -97.8% |
| Cash/sh | 0.1 | P/FCF | - | Sales past 3/5Y | 77.98% 164.15% | ROIC | - | 52W Low | 23.4% ($0.16) | Perf 3Y | -98.81% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 21.31% | Gross Margin | 53.07% | Volatility(W/M) | 13.06% 9.74% | Perf 5Y | -99.73% |
| Dividend TTM | - | EV/Sales | 5.14 | Sales Y/Y TTM | 86.32% | Oper. Margin | -790.23% | ATR (14) | 0.02 | Perf 10Y | -99.75% |
| Dividend Ex-Date | - | Quick Ratio | 0.3 | EPS Q/Q | 30.54% | Profit Margin | -1061.82% | RSI (14) | 39.71 | Recom | 1.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.3 | Sales Q/Q | -1.97% | SMA20 | 1.85% ($0.19) | Beta | 1.14 | Target Price | $8.04 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/13 | SMA50 | -26.37% ($0.26) | Rel Volume | 0.1 | Prev Close | $0.21 |
| Employees | 75 | LT Debt/Eq | - | EPS/Sales Surpr. | -49.78% -4% | SMA200 | -90.85% ($2.08) | Avg Volume(3M) | 8.59M | Price | $0.19 |
| IPO | 2007/4/25 | Option/Short | Yes/Yes | Trades | 543 | Volume | 850,523 | Change | -8.14% |
🧫 VolitionRX is a Belgium-based in-vitro diagnostics company developing and commercializing its proprietary Nu.Q® diagnostic platform, which measures nucleosomes in the blood. Its key indications include early cancer detection, sepsis and NET (neutrophil extracellular trap) assessment, and the veterinary diagnostics field. The company is expanding commercialization through licensing agreements with global diagnostics majors such as Werfen and Hologic, and is a micro-cap stock listed on NYSE American.
Over the past 1 year, on the lower side
98% below its 1-year high.
Traded less than usual. That is 10% of its average volume.
VNRX has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +56.0% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $219. Peers typically go for $145.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.7%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 7.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #122 of 140 in the industry
Based on market cap of $5M.
FAQ
What kind of company is VNRX?
VNRX belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of VNRX?
The market cap of VNRX is approximately $5M, ranking 5,595 within its sector.
What is the 52-week high and low for VNRX?
VNRX has recorded a 52-week high of $9.50 and a low of $0.16.
